Tadalafil vs Tamsulosin for the Management of Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia: A Randomised Clinical Trial

Tadalafil vs Tamsulosin for the Management of Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia: A Randomised Clinical Trial

Introduction: Tadalafil and tamsulosin have both been approved for use in the management of Lower Urinary Tract Symptoms (LUTS). Limited studies have shown the efficacy of tadalafil in terms of maximum urinary output flow (Qmax) and post-void residual (PVR). Aim: To compare the efficacy of tadalafi...

Full description

Bibliographic Details
Main Authors:	A Venkata Ranga Swamy, Jandhyam Manikantan, D Raja Reddy, Mutyasri Pedapathnapu, K Sitha Ramaiah, A Bhagavan
Format:	Article
Language:	English
Published:	JCDR Research and Publications Pvt. Ltd. 2023-09-01
Series:	International Journal of Anatomy Radiology and Surgery
Subjects:	international prostate symptom score phosphodiesterase-5 inhibitors quality of life uroselective alpha-blocker
Online Access:	https://www.ijars.net/articles/PDF/2918/61995_CE[Ra1]_F(SHU)_PF1(HB_SHU_OM)_QC(SHK_RDW_SHU)_PFA(SHU)_PN(SHU).pdf

Similar Items

Non‑Hormonal treatment of BPH/BOO
by: Nadir I Osman, et al.
Published: (2014-01-01)

Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
by: Daisuke Gotoh, et al.
Published: (2022-09-01)

Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study
by: Malik Suhail Ahmad, et al.
Published: (2022-01-01)

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Tamsulosin Plus Tadalafil Compared With Tamsulosin Alone in Treating Males With Lower Urinary Tract Symptoms Secondary to Benign Prostrate Hyperplasia
by: Rui Zhou, et al.
Published: (2023-02-01)

Non-interventional (observational) study of application of the tamsulosin (Proflosin®) in patients with benign prostatic hyperplasia in routine clinical practice
by: L. G. Spivak, et al.
Published: (2015-02-01)

Non-interventional (observational) study of application of the tamsulosin (Proflosin®) in patients with benign prostatic hyperplasia in routine clinical practice
by: L. G. Spivak, et al.
Published: (2015-02-01)

Effectiveness of tadalafil and tamsulosin combination in benign prostatic hyperplasia: A prospective cohort study at a tertiary care center
by: Sudarsan S, et al.
Published: (2023-08-01)

Clinical Characteristics and Management of Renal Trauma: A Single-centre Observational Study
by: A Venkata Ranga Swamy, et al.
Published: (2023-01-01)

Efficacy and safety of a combined use of alpha1-blocker doxazosin and phosphodiesterase-5 inhibitor udenafil in patients with benign prostatic hyperplasia
by: S. K. Martazinova, et al.
Published: (2014-11-01)

The effect of different doses of tamsulosin on lower urinary tract symptoms in patients with benign prostatic hyperplasia
by: Ramin Haghighi, et al.
Published: (2022-09-01)

Erratum: Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study
Published: (2019-01-01)

Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)
by: Jessica C. Hassel, et al.
Published: (2017-09-01)

Evaluation of intermittent tamsulosin in treating symptomatic patients with benign prostatic hyperplasia
by: Mohamed G Soliman, et al.
Published: (2023-01-01)

Effect of Roflumilast in airways disorders via dual inhibition of phosphodiesterase and Ca2+-channel
by: Faisal Imam, et al.
Published: (2020-06-01)

Does the Daily Dose of Tadalafil for the Treatment of Erectile Dysfunction Increase Penile Sensation?
by: Selim Taş, et al.
Published: (2023-03-01)

Original and generic Tamsulosin: is there a difference?
by: SK Zyryanov, et al.
Published: (2014-12-01)

Health-Care Resource Utilization and Treatment Patterns in Men with Erectile Dysfunction and Benign Prostatic Hyperplasia-Associated Lower Urinary Tract Symptoms in the United States: A Retrospective Database Study
by: Goldstein I, et al.
Published: (2023-09-01)

Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review
by: Arman Shafiee, et al.
Published: (2023-05-01)

Tadalafil Nanoemulsion Mists for Treatment of Pediatric Pulmonary Hypertension via Nebulization
by: Bassant Elbardisy, et al.
Published: (2022-12-01)

Can We Use the Silodosin as Second Line Treatment of Benign Prostate Hyperplasia?
by: Bekir Voyvoda, et al.
Published: (2021-09-01)

BENIGN PROSTATIC HYPERPLASIA: A POSSIBILITY TO USE TYPE 5 PHOSPHOESTERASE INHIBITORS
by: A. O. VASILIEV, et al.
Published: (2016-12-01)

Improvement of Urodynamic Indices by Single Dose Oral Tadalafil in Men With Supra Sacral Spinal Cord Injury
by: Karim Taie, et al.
Published: (2010-12-01)

The relaxant effect of Tamsulosin in the vascular reactivity of goat isolated renal artery
by: Aveen Muhsin Asaad, et al.
Published: (2019-08-01)

Use of alpha-blockers to relieve lower urinary tract symptoms in benign prostatic hyperplasia
by: GG Krivoborodov
Published: (2014-12-01)

Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride
by: Kirill V. Kosilov, et al.
Published: (2020-06-01)

Fixed and separate combination of solifenacin and tamsulosin in urinary disorders associated with benign prostatic hyperplasia: a choice based on price and value comparison
by: A. G. Tolkushin, et al.
Published: (2019-08-01)

Effect of Tamsulosin Use on Plasma Insulin Status in Benign Prostatic Hyperplasia Patients in Sokoto, Nigeria
by: M Dikko, et al.
Published: (2020-05-01)

EFFECTIVENESS AND SAFETY OF THE «DE ALEX» BIO COMPLEX AS MONOTHERAPY AND IN COMBINATION WITH TAMSULOSIN IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
by: P. A. Scheplev, et al.
Published: (2017-11-01)

The use of tamsulosin in the treatment of 10–15 mm lower ureteral stones in adults: a double-blinded randomized controlled trial
by: Mahmoud M. Shalaby, et al.
Published: (2022-10-01)

Clinical Implication of Phosphodiesterase-4-Inhibition
by: Martin Alexander Schick, et al.
Published: (2022-01-01)

Dual Inhibition of Phosphodiesterase and Ca<sup>++</sup> Channels Explains the Medicinal Use of <i>Balanites aegyptiaca</i> (L.) in Hyperactive Gut Disorders
by: Najeeb Ur Rehman, et al.
Published: (2022-04-01)

PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
by: N. A. Avxentyev, et al.
Published: (2016-09-01)

Tadalafil versus tamsulosin for distal ureteric stone expulsion; a prospective randomized comparative study
by: Ahmed M. Ragheb, et al.
Published: (2024-04-01)

Long-term protective effect of tadalafil on spermatogenesis following testicular ischemia-reperfusion injury in a rat model
by: Bomi Kim, et al.
Published: (2022-05-01)

Changes of resistance indices after medication in benign prostatic hyperplasia: a prospective study
by: Dong Jin Park, et al.
Published: (2023-09-01)

Comparative study between Tamsulosin, Silodosin and Tadalaﬁl as a medical expulsive therapy for lower ureteral stones
by: Mohammad Ahmad Abdelaal, et al.
Published: (2023-02-01)

Tamsulosin vs. Tadalafil as medical expulsive therapy for distal ureteral stones: a systematic review and meta-analysis
by: Mikhael Belkovsky, et al.
Published: (2024-03-01)

Calcium channel blockers- Induced iatrogenic gingival hyperplasia: Case series
by: G Agnes Golda Priyadarshini, et al.
Published: (2023-01-01)

Evidence for benefits and risks of tadalafil as a non-prescription medicine: review and evaluation using the Group Delphi technique to achieve consensus amongst clinical experts
by: Kurt Miller, et al.
Published: (2023-10-01)

Floppy iris syndrome prediction in patients with age-related cataract and benign prostatic hyperplasia
by: A. A. Shpak, et al.
Published: (2016-07-01)